Abuse-related and abuse-limiting effects of methcathinone and the synthetic "bath salts" cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats

Psychopharmacology

Volumn 231, Issue 1, 2014, Pages 199-207

  Bonano, J S ^a   Glennon, R A ^a   De Felice, L J ^a   Banks, M L ^a   Negus, S S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Drug abuse; Intracranial self stimulation; Mephedrone; Methcathinone; Methylenedioxypyrovalerone; Methylone; Rat

Indexed keywords

3,4 METHYLENEDIOXYPYROVALERONE; 4' METHYLMETHCATHINONE; METHCATHINONE; METHYLONE; PYROVALERONE; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABUSE; DRUG EFFICACY; DRUG POTENCY; MALE; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; PRIORITY JOURNAL; RAT; SELF STIMULATION;

ANIMALS; BENZODIOXOLES; BRAIN; CONDITIONING, OPERANT; DATA INTERPRETATION, STATISTICAL; DESIGNER DRUGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; INJECTIONS; MALE; METHAMPHETAMINE; PROPIOPHENONES; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; SELF ADMINISTRATION; SELF STIMULATION; SUBSTANCE-RELATED DISORDERS;

EID: 84891829217     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3223-5     Document Type: Article

References (41)

1. Aarde SM, Angrish D, Barlow DJ, Wright MJ, Vandewater SA, Creehan KM, Houseknecht KL, Dickerson TJ, Taffe MA (2013) Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. Addict Biol. doi: 10.1111/adb.12038
2. Altarifi AA, Negus SS (2011) Some determinants of morphine effects on intracranial self-stimulation in rats: dose, pretreatment time, repeated treatment, and rate dependence. Behav Pharmacol 22:663-673
3. Bauer CT, Banks ML, Blough BE, Negus SS (2013a) Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats. Brit J Pharm 168:850-862
4. Bauer CT, Banks ML, Blough BE, Negus SS (2013b) Rate-dependent effects of monoamine releasers on intracranial self-stimulation in rats: implications for abuse liability assessment. Behav Pharmacol 24:448-458. doi: 10.1097/FBP.0b013e328363d1a4
5. Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV (2012a) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37:1192-1203. doi: 10.1038/npp.2011.304
6. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW (2012b) Powerful cocaine-like actions of 3,4- methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology 38(4):552-562. doi: 10.1038/npp.2012.204
7. Cameron K, Kolanos R, Verkariya R, De Felice L, Glennon RA (2013a) Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of "bath salts", produce opposite effects at the human dopamine transporter. Psychopharm 227(3):493-499. doi: 10.1007/s00213-013-2967-2
8. Cameron KN, Kolanos R, Solis E, Glennon RA, De Felice LJ (2013b) Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. Br J Pharmacol 168:1750-1757
9. Carlezon WA Jr, Chartoff EH (2007) Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc 2:2987-2995
10. Cozzi NV, Sievert MK, Shulgin AT, Jacob P, Ruoho AE (1999) Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Eur J Pharm 381:63-69
11. Cozzi NV, Brandt SD, Daley PF, Partilla JS, Rothman RB, Tulzer A, Sitte HH, Baumann MH (2013) Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. Eur J Pharm 699:180-187
12. Dal Cason TA, Young R, Glennon RA (1997) Cathinone: an investigation of several n-alkyl and methylenedioxy-substituted analogs. Pharm Biochem Behav 58:1109-1116
13. Esposito RU, Motola AH, Kornetsky C (1978) Cocaine: acute effects on reinforcement thresholds for self-stimulation behavior to the medial forebrain bundle. Pharmacol Biochem Behav 8:437-439
14. Esposito RU, Perry W, Kornetsky C (1980) Effects of d-amphetamine and naloxone on brain stimulation reward. Psychopharmacology 69:187-191
15. Fantegrossi WE, Gannon BM, Zimmerman SM, Rice KC (2013) In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology 38:563-573
16. Glennon RA, Yousif M, Naiman N, Kalix P (1987) Methcathinone: a new and potent amphetamine-like agent. Pharm Biochem Behav 26:547-551
17. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE (2011) 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339:530-536
18. Kalix P, Glennon RA (1986) Further evidence for an amphetamine-like mechanism of action of the alkaloid cathinone. Biochem Pharmacol 35:3015-3019
19. Kaminski BJ, Griffiths RR (1994) Intravenous self-injection of methcathinone in the baboon. Pharmacol Biochem Behav 47:981-983
20. Kornetsky C, Esposito RU (1979) Euphorigenic drugs: effects on the reward pathways of the brain. Fed Proc 38:2473-2476
21. Kyle PB, Iverson RB, Gajagowni RG, Spencer L (2011) Illicit bath salts: not for bathing. J Miss State Med Assoc 52:375-377
22. López-Arnau R, Martínez-Clemente J, Pubill D, Escubedo E, Camarasa J (2012) Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br J Pharmacol 167:407-420
23. Marusich JA, Grant KR, Blough BE, Wiley JL (2012) Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice. Neurotoxicology 33:1305-1313
24. McElrath K, O'Neill C (2011) Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply. Int J Drug Policy 22:120-127
25. Miliaressis E, Rompre PP, Laviolette P, Philippe L, Coulombe D (1986) The curve-shift paradigm in self-stimulation. Physiol Behav 37:85-91
26. Motbey CP, Clemens KJ, Apetz N, Winstock AR, Ramsey J, Li KM, Wyatt N, Callaghan PD, Bowen MT, Cornish JL, McGregor IS (2013) High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: neural consequences and comparison with methamphetamine. J Psychopharmacol. doi: 10.1177/0269881113490325
27. National Research Council (2011) Guide for the care and use of laboratory animals, Eighth Edition. The National Academies Press: Washington, DC
28. Nielsen JA, Schechter MD (1985) Behavioral and neurochemical effects of (-)- and (+/-)-cathinone: dose-response and time-course. Prog Neuropsychopharmacol Biol Psychiatry 9:739-743
29. Olds ME, Yuwiler A (1992) Effects of acute and chronic fenfluramine on self-stimulation and its facilitation by amphetamine. Eur J Pharmacol 216:363-372
30. Robinson JE, Agoglia AE, Fish EW, Krouse MC, Malanga CJ (2012) Mephedrone (4-methylmethcathinone) and intracranial self-stimulation in C57BL/6J mice: comparison to cocaine. Behav Brain Res 234:76-81
31. Rosenauer R, Luf A, Holy M, Freissmuth M, Schmid R, Sitte HH (2013) A combined approach using transporter-flux assays and mass spectrometry to examine psychostimulant street drugs of unknown content. ACS Chem Neurosci 4:182-190
32. Rosenberg MB, Carroll FI, Negus SS (2013) Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in rats. J Pain 4:246-259
33. Shortall SE, Macerola AE, Swaby RTR, Jayson R, Korsah C, Pillidge KE, Wigmore PM, Ebling FJP, Green AR, Fone KCF, King MV (2012) Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. Eur Neuropsychopharmacol. doi: 10.1016/j.euroneuro. 2012.09.005
34. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458-470
35. Spiller HA, Ryan ML, Weston RG, Jansen J (2011) Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol 49:499-505
36. Vardakou I, Pistos C, Spiliopoulou C (2011) Drugs for youth via internet and the example of mephedrone. Toxicol Lett 201:191-195
37. Vlachou S, Markou A (2011) Intracranial self-stimulation. In: Olmstead MC (ed) Animal models of drug addiction. Humana, Totowa, pp 3-56
38. Wagner GC, Preston K, Ricaurte GA, Schuster CR, Seiden LS (1982) Neurochemical similarities between d, l-cathinone and d-amphetamine. Drug Alcohol Depend 9:279-284
39. Watterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF, Marusich JA, Wegner S, Olive MF (2012) Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict Biol. doi: 10.1111/j.1369-1600.2012.00474.x
40. Wise RA (1996) Addictive drugs and brain stimulation reward. Annu Rev Neurosci 19:319-340
41. Young R, Glennon RA (1998) Discriminative stimulus effects of S(-)-methcathinone (CAT): a potent stimulant drug of abuse. Psychopharmacology 140:250-256